ATMP Manufacturing Protocols at ISPE Biopharmaceutical Manufacturing Conference!

Peter Walters and JP Bornholdt are presenting “ATMP Drug Products: Training for the Marathon” at the ISPE Biopharmaceutical Manufacturing Virtual Conference!

Join Peter Walters and JP Bornholdt, ATMP SMEs from CRB, on Tuesday, June 2^nd at 12:30 pm EST, as they discuss the importance of establishing proper manufacturing protocols early in the development phase and why this is crucial to the long term goal of getting ATMP therapies to patients as quickly as possible.

Modeling multiple variations of a typical gene-modified cell therapy facility, CRB shows how early development efforts can directly affect your clinical and commercial facility design, cost and execution.

A number of challenges remain in the manufacture of these therapies, especially as we look to move to commercial-scale production. These challenges have caused industry participants to express concerns that the manufacturing shortage would threaten industry growth and lengthen time-to-market for these living therapies. While the industry is hyper-focused on racing to the finish line as fast as possible, we should consider the criticality of long term needs and how future-proofing manufacturing facilities by establishing proper manufacturing protocols in the development phase is crucial to getting ATMP therapies to patients.

To register for this event, click here. 
Tuesday, June 2^nd
12:30 pm EST